Thiazine-derived compounds in inhibiting efflux pump in Staphylococcus aureus K2068, mepA gene expression, and

Priscilla R Freitas1, Ana C J de Araújo1, Isaac M Araújo1

  • 1Department of Biological Chemistry, Universidade Regional do Cariri, Crato-CE, Brazil.

Insights

Thiadiazine compounds were tested against Staphylococcus aureus efflux pumps. Compound IJ17 showed significant inhibition of the MepA efflux pump and altered bacterial membrane permeability, suggesting a new strategy against antibiotic resistance.

Area of Science:

  • Microbiology
  • Medicinal Chemistry

Background:

  • Staphylococcus aureus exhibits multidrug resistance, with efflux pumps being a key mechanism.
  • The MepA efflux pump is a significant contributor to antibiotic resistance in S. aureus.

Purpose of the Study:

  • To evaluate the potential of thiadiazine-derived compounds in inhibiting the MepA efflux pump.
  • To investigate the mechanism of action of these compounds against S. aureus.

Main Methods:

  • Minimum Inhibitory Concentration (MIC) and efflux pump inhibition assays.
  • Gene expression analysis of mepA, membrane permeability tests, and in silico molecular docking.
  • Testing of thiadiazine compounds (IJ-14 to IJ-20) against S. aureus K2068.

Main Results:

  • Compounds IJ17 and IJ20 demonstrated direct activity against S. aureus.
  • IJ17 significantly inhibited mepA gene expression and altered membrane permeability.
  • Molecular docking provided insights into the interaction of compounds with the efflux pump.

Conclusions:

  • Thiadiazine-derived compounds, particularly IJ17, show promise in combating S. aureus multidrug resistance.
  • IJ17 exhibits potential as an efflux pump inhibitor, offering a novel approach to overcome resistance mechanisms.